Clopidogrel
Chemical
A thienopyridine
Use
↓atherothrombotic events in patients with atherosclerotic disease
Presentation
Tablets
Dose
Prophylactic: 75mg PO
ACS + aspirin: 300mg PO
Route
PO
Onset
2 hrs
DoA
Platelet aggregation returns to normal 5 days after Tx withdrawal → requires new platelet synthesis
MoA
PRODRUG – requires activation – absorbed in intestine & activated in liver through two sequential oxidative steps
- Inhibits binding of ADP to P2Y12 receptor
- ∴ prevents ADP-mediated activation of GP IIb/IIIa
- Irreversible
PD
CVS: platelet aggregation inhibition
PK
A
OBA 50%
D
98% PPB
M
85% hepatic esterases → INACTIVE
15% by Cytochrome P450 → ACTIVE DRUG
E
Metabolites excreted in urine & faeces
Adverse Effects
- ↑risk GI bleeding
- TTP
INTERACTIONS
- + any anti-clotting drug = HUGE risk of bleeding
- CYP2C19 poor metabolisers → ↓response with Clopidogrel
- AVOID OMEPRAZOLE because metabolised by CYP2C19
Monitoring
- Generally not performed, but platelet aggregometry can be used
- PF100 (not available everywhere) – formally know as the Dade Behring platelet function analyzer
Reversal
- Platelet transfusion